Compare Amphastar Pharmaceuticals Inc (AMPH) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Gitlab Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.48 (market cap $826.08M), while Gitlab Inc trades at $33.63 (market cap $5.48B). The key difference: Gitlab Inc is far larger — about 6.6× Amphastar Pharmaceuticals Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | GTLB | |
|---|---|---|
Market Cap | $826.08M | $5.48B |
Sector | Health | Technology |
52-Week High | $30.81 | $51.04 |
52-Week Low | $16.87 | $19.42 |
Enterprise Value | $1.22B | $4.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
GitLab (GTLB) trades at $32.42, down 4.25% today, but maintains a bullish technical outlook with strong moving average signals. The company shows impressive revenue growth, reaching $759 million in 2025, with consistent earnings beats in recent quarters. Analyst sentiment is mixed with 36.7% buy ratings, while the stock trades near consensus price target of $31.93. Recent news highlights GitLab's leadership in DevSecOps and strategic AI partnerships.
GitLab presents a growth story with strong market positioning but faces profitability challenges. The stock offers upside potential from AI-driven software demand and enterprise adoption, though high valuation multiples and negative cash flow pose risks. Investors should weigh the company's strategic position against its path to sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
